Disease

Thyroid Carcinoma, Anaplastic

Late-stage therapeutic developmentEmerging researchRising momentum

MeSHThyroid Carcinoma, Anaplastic

Publications

Clinical trials

Related conditions

2024

Latest publication

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this disease.

A distinct tumor microenvironment makes anaplastic thyroid cancer more lethal but immunotherapy sensitive than papillary thyroid cancer.

Research2024-03-07JCI insight

Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.

Research2022-08-01Journal of the National Comprehensive Cancer Network : JNCCN

Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers.

Research2016-02-15The Journal of clinical investigation

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Low

Key developments

1 clinical trial expected to report results, the earliest in Q4 2029.

Upcoming Milestones

Q4 2029DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial): An Umbrella-Basket Platform Trial to Evaluate the Efficacy of Targeted Therapies in Rare Adult, Paediatric and Teenage/Young Adult (TYA) Cancers With Actionable Genomic Alterations, Including Common Cancers With Rare Actionable Alterations. Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.

Major developments

Upcoming trial readoutImportant

DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial): An Umbrella-Basket Platform Trial to Evaluate the Efficacy of Targeted Therapies in Rare Adult, Paediatric and Teenage/Young Adult (TYA) Cancers With Actionable Genomic Alterations, Including Common Cancers With Rare Actionable Alterations. Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.

Results expected Q4 20292025-11-24

Clinical Milestones1View

Results expected 1

2025-11-24DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial): An Umbrella-Basket Platform Trial to Evaluate the Efficacy of Targeted Therapies in Rare Adult, Paediatric and Teenage/Young Adult (TYA) Cancers With Actionable Genomic Alterations, Including Common Cancers With Rare Actionable Alterations. Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.Results expected Q4 2029

Activity timeline1

2025-11-24ClinicalDETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial): An Umbrella-Basket Platform Trial to Evaluate the Efficacy of Targeted Therapies in Rare Adult, Paediatric and Teenage/Young Adult (TYA) Cancers With Actionable Genomic Alterations, Including Common Cancers With Rare Actionable Alterations. Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.Results expected Q4 2029

Clinical trials

2 sponsors · 0 new · 0 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme

All trials

Active

Late-stage

Completed

Late-stage studies

Phase 2/3 · Recruiting · Cancer Research UK

Recruiting

Phase 2/3 · Recruiting · Cancer Research UK

Research activity

3 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time

20162024

Most influential

Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers.

The Journal of clinical investigation · 2016 · 925 cites

Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.

Journal of the National Comprehensive Cancer Network : JNCCN · 2022 · 363 cites

A distinct tumor microenvironment makes anaplastic thyroid cancer more lethal but immunotherapy sensitive than papillary thyroid cancer.

JCI insight · 2024 · 42 cites

Recent publications

A distinct tumor microenvironment makes anaplastic thyroid cancer more lethal but immunotherapy sensitive than papillary thyroid cancer.

JCI insight · 2024 · 42 cites

Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.

Journal of the National Comprehensive Cancer Network : JNCCN · 2022 · 363 cites

Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers.

The Journal of clinical investigation · 2016 · 925 cites

Major themes8

Thyroid Carcinoma, Anaplastic2
Thyroid Neoplasms2
Adenocarcinoma1
Chemokine CXCL131
Immunotherapy1
Iodine1
Thyroid Cancer, Papillary1
Transcriptome1

Leading journals3

JCI insight1
Journal of the National Comprehensive Cancer Network : JNCCN1
The Journal of clinical investigation1

Leading researchers8

Ball D1
Berger MF1
Bernet V1
Bischoff L1
Blomain E1
Boucai L1
Busaidy NL1
Campbell M1

Affiliations (unnormalised)6

Abramson Cancer Center at the University of Pennsylvania.1
Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute.1
City of Hope National Medical Center.1
Dana-Farber/Brigham and Women's Cancer Center.1
Department of Clinical Oncology1
Duke Cancer Institute.1

Related conditions

1 match

Diseases frequently studied alongside this one. Number shows shared papers.

Thyroid Neoplasms3

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

An aggressive THYROID GLAND malignancy which generally occurs in IODINE-deficient areas in people with previous thyroid pathology such as GOITER. It is associated with CELL DEDIFFERENTIATION of THYROID CARCINOMA (e.g., FOLLICULAR THYROID CARCINOMA; PAPILLARY THYROID CANCER). Typical initial presentation is a rapidly growing neck mass which upon metastasis is associated with DYSPHAGIA; NECK PAIN; bone pain; DYSPNEA; and NEUROLOGIC DEFICITS.

Identifiers

MeSHThyroid Carcinoma, Anaplastic

References & data sources

Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
Related entities are derived from literature co-mention (studied together) — associative, not causal.